Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218315 · ClinicalTrials.gov registry record · NA
Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma
A NA study, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT07218315: Recruiting NA study, sponsored by M.D. Anderson Cancer Center.
NCT07218315 is a NA study that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07218315, a NA study, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study is to evaluate the effectiveness of nsPFA in treating papillary thyroid microcarcinoma. T
Interventions
- DEVICE CellFX nsPFA Percutaneous Electrode System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-02-11 |
| Est. Completion | 2031-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07218315
The ClinicalTrials.gov registry entry for NCT07218315 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CellFX nsPFA Percutaneous Electrode System is the first listed.
NCT07218315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07218315 about?
NCT07218315 is a clinical study titled "Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma". This study is to evaluate the effectiveness of nsPFA in treating papillary thyroid microcarcinoma. T
What is the current status of trial NCT07218315?
This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2026-02-11. Estimated completion is 2031-01-31.
What interventions are being tested in trial NCT07218315?
The interventions under investigation include: CellFX nsPFA Percutaneous Electrode System (DEVICE).
Who is sponsoring clinical trial NCT07218315?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.